Magazine Article | September 24, 2018

Rollout Begins Of Trump's Drug Blueprint

Source: Life Science Leader

By John McManus, The McManus Group

The Trump administration disrupted the typically sleepy August recess with a frenetic release of proposals that implement components of its “blueprint” on drug pricing. The proposals are intended to strengthen the negotiating leverage of Medicare plans over pharmaceutical manufacturers, but physician and patient advocates expressed concern that they may result in impaired patient access to needed drug therapy.